Why do we need drugs to treat the patient with obesity?
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Objective: Obesity is a public health problem, which increases the risk of chronic diseases and mortality. Weight loss can reduce mortality and improve most of the detrimental health consequences of obesity. Design and Methods: This paper was developed from two presentations to the US Food and Drug Administration (FDA), which has responsibility for reviewing and approving drugs to treat obesity. Results: A weight loss of 5% or more is sufficient to significantly reduce health risks in individuals with impaired glucose tolerance, hypertension, or nonalcoholic fatty liver disease. Slightly more weight loss (16% on average, achieved by surgery) reduces mortality. The goal of medicating for obesity is to help more patients achieve more weight loss. A barrier to drug approval has been the concern that weight loss medications might be used by individuals with little or no health risks, thus mandating a low side effect profile for approval of any drug. This limits the options for patients who have obesity‐related health problems that could improve with weight loss. Recently the FDA signaled interest in identifying health benefits in higher risk patients that might justify medications with higher risk; however, the potential impact on a large segment of the population has led the FDA to consider requiring a cardiovascular outcome trial for all obesity medications, either prior to or after approval. Conclusion: This review argues that drugs are needed for obesity because they enhance behaviorally induced weight loss and that new medications for obesity are needed in the approval process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Prevalence of High Body Mass Index in US Children and Adolescents, 2007-2008
Ogden, C. L. (2010) · JAMA · doi:10.1001/jama.2009.2012 · Cited by 3,200
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“This benefit of weight loss on diabetes has also been shown in both the Diabetes Prevention Program and Look AHEAD Trial, where weight loss is associated with improvement in cardiometabolic risk factors in people with diabetes or at risk for developing diabetes (32-36).”
ResultLong-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · cited 1×
“Comparing large samples of individuals who had gastric by-pass surgery with matched controls, Adams et al (28) showed that those with a gastric by-pass had a lower mortality and decreased deaths from cardiovascular disease and cancer.”
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Self-citationChurch, T. S., Thomas, D. M., Tudor-Locke, C., Katzmarzyk, P. T., Earnest, C. P., Rodarte, R. Q., Martin, C. K., Blair, S. N., & Bouchard, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019657 · Cited by 1,294 · cited 1×
“the abundance of good tasting foods (9,10), much of it available at low, and sometimes subsidized, prices (11) and a society in which physical exertion and recreational physical activity are often at low levels (12).”
Background(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948 · cited 1×
“This benefit of weight loss on diabetes has also been shown in both the Diabetes Prevention Program and Look AHEAD Trial, where weight loss is associated with improvement in cardiometabolic risk factors in people with diabetes or at risk for developing diabetes (32-36).”
ResultEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 2×
“This is illustrated with the SCOUT (54,55).”
BackgroundMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 2×
“The lower right-hand figure shows the weight loss and 95% confidence interval for the 5 years incidence of the primary end-point in the SCOUT trial based on weight loss during the first 6 weeks (44).”
BackgroundMethodWeight Bias among Health Professionals Specializing in Obesity
Schwartz, M. B., Chambliss, H. O., Brownell, K. D., Blair, S. N., & Billington, C. (2003) · Obesity Research · doi:10.1038/oby.2003.142 · Cited by 884 · cited 1×
“Health care professionals often hold to the assumption that obesity can be prevented by selfcontrol, that patient’s noncompliance explains the failure of weight loss, and that obesity is caused by emotional problems (24-26).”
BackgroundBariatric surgery and prevention of type 2 diabetes in Swedish obese subjects
Carlsson, L. M. S., Peltonen, M., Ahlin, S., Anveden, Å., Bouchard, C., Carlsson, B., Jacobson, P., Lönroth, H., Maglio, C., Näslund, I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112082 · Cited by 794
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665 · cited 3×
“An analysis of weight loss by Douketis et al (49) found, as did Leblanc et al (43), that diet/lifestyle produced < 5 kg weight loss after 2-4 years and that pharmacologic therapy provides 5-10 kg after 1-2 years.”
BackgroundMethodPsychosocial origins of obesity stigma: toward changing a powerful and pervasive bias
Puhl, R. M., & Brownell, K. D. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00122.x · Cited by 623
Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes
Foster, G. D., Sanders, M. H., Millman, R., Zammit, G., Borradaile, K. E., Newman, A. B., Wadden, T. A., Kelley, D., Wing, R. R., Pi Sunyer, F. X., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1776 · Cited by 600
Four-year weight losses in the Look AHEAD study: factors associated with long-term success
Wadden, T. A., Neiberg, R. H., Wing, R. R., Clark, J. M., Delahanty, L. M., Hill, J. O., Krakoff, J., Otto, A., Ryan, D. H., Vitolins, M. Z., et al. (2011) · Obesity · doi:10.1038/oby.2011.230 · Cited by 465
Haddock, C., Poston, W., Dill, P., Foreyt, J., & Ericsson, M. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801889 · Cited by 303
Lifestyle change and mobility in obese adults with type 2 diabetes
Rejeski, W. J., Ip, E. H., Bertoni, A. G., Bray, G. A., Evans, G., Gregg, E. W., & Zhang, Q. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110294 · Cited by 301 · cited 1×
“Both impaired mobility (40) and sleep apnea benefit from weight loss (41).”
BackgroundSelf-citationWilliamson, D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.544 · Cited by 244
Effect of a Stepped-Care Intervention Approach on Weight Loss in Adults: A Randomized Clinical Trial
Jakicic, J. M., Tate, D. F., Lang, W., Davis, K. K., Polzien, K., Rickman, A. D., Erickson, K., Neiberg, R. H., & Finkelstein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.6866 · Cited by 158
Phelan, S., Kanaya, A. M., Subak, L. L., Hogan, P. E., Espeland, M. A., Wing, R. R., Burgio, K. L., DiLillo, V., Gorin, A. A., West, D. S., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2011.10.139 · Cited by 107 · cited 1×
“Weight loss in the range of 5-10% has also been associated with improved mobility, reduction in signs and symptoms of sleep apnea and improvement in symptoms of urinary stress incontinence in women (49,41,51).”
BackgroundFood and Drug Administration's Obesity Drug Guidance Document: A Short History
Colman, E. (2012) · Circulation · doi:10.1161/circulationaha.111.028381 · Cited by 101
Cited by
Saad, F., Yassin, A., Doros, G., & Haider, A. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.139 · Cited by 131
(2016) · PubMed Central · Cited by 77
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Combination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38
Park, J. S., Kwon, J., Choi, H. J., & Lee, C. (2021) · Medicine · doi:10.1097/md.0000000000023780 · Cited by 27
Metadata
- Authors
- Bray, G. A.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2013-05
- Volume
- 21
- Issue
- 5
- Pages
- 893-899
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W1971328164
- Cited by
- 38
- References
- 28
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.